TherapeuticsMD, Inc. — Director's Dealing 2023

Feb 22, 2023

SEC Form 4/A — Form 4/A

Issuer: TherapeuticsMD, Inc. (TXMD)
CIK: 0000025743
Period of Report: 2022-12-30

Reporting Person: Rubric Capital Management LP (Director, 10% Owner, See remarks)
Reporting Person: Rosen David Efraim (Director, 10% Owner, See remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-12-30	Series A Preferred Stock, par value $0.001 per share	D	29000	$1333	Disposed	0	Indirect

Footnotes

F1: The Series A Preferred Stock was mandatorily redeemed by the Issuer pursuant to Section 6(b) of the Certificate of Designation, Preferences and Rights of Series A Preferred Stock, establishing the powers designations, preferences and privileges, and the qualifications, limitations or restrictions of the Series A Preferred Stock (the "Series A Preferred Stock COD") at a redemption price of $1,333 per share. A copy of Series A Preferred Stock COD was filed by the Issuer as Exhibit 3.1 of the Current Report on Form 8-K filed by the Issuer with the Securities and Exchange Commission on August 1, 2022.

F2: This Form 4 is filed by Rubric Capital Management LP ("Rubric Capital") and Mr. David Rosen, with respect to the securities held by certain funds and/or accounts (collectively, the "Rubric Vehicles"). Rubric Capital serves as the investment adviser to the Rubric Vehicles. Mr. David Rosen serves as the Managing Member of Rubric Capital Management GP, LLC, the general partner of Rubric Capital. The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.